Combination therapy may improve immune response against advanced prostate cancer

Combining the targeted therapy olaparib with an further immunotherapy whitethorn amended immune effect successful a subgroup of patients with metastatic castration-resistant prostate crab who responded poorly to archetypal treatment, according to a Northwestern Medicine survey published successful The Journal of Clinical Investigation.